Black Diamond Therapeutics reports Q2 net loss of $9.9 million, no revenue in either quarter
Black Diamond Therapeutics reported second-quarter 2026 results with a net loss of $9.9 million, narrowed from $10.6 million a year earlier. The company had no revenue in either quarter, and its six-month results swung to a net loss of $18.9 million from net income of $46.0 million in 2025, which included $70.0 million of license revenue. Cash, cash equivalents, and investments were $110.5 million at June 30, 2026, which the company says will fund operations into the second half of 2028.
Key points
- Q2 2026 net loss was $9.9 million, compared with $10.6 million in Q2 2025.
- Six-month net loss was $18.9 million, compared with net income of $46.0 million in the first half of 2025, which included $70.0 million of license revenue.
- Cash, cash equivalents, and investments were $110.5 million at June 30, 2026, down from $128.7 million at December 31, 2025.
- The company plans to provide an update on silevertinib's pivotal development path and FDA feedback in Q4 2026.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.